WATCH: Former Pfizer Europe Chief Toxicologist Testifies Pfizer Vaccine Should Never Have Been Released, Calls Mass Rollout a “Human Experiment”

Key Takeaways

• Former Pfizer Europe toxicologist testified to German parliament in March 2026.
• He claimed carcinogenicity and reproductive toxicity studies were omitted.
• Testimony alleges 1,200 reported deaths, possibly up to 60,000 in Germany.
• Claims vaccine batch differed, using E. coli production method.
• Calls mass rollout a prohibited human experiment.

Pulse Analysis

The March 2026 testimony by Dr. Sterz, a former Pfizer Europe chief toxicologist, adds a new layer to ongoing debates about COVID‑19 vaccine safety. By asserting that essential carcinogenicity and reproductive toxicity studies were bypassed, the former insider challenges the rigor of the emergency use authorization process that enabled Comirnaty’s rapid deployment across Europe. His claim that the commercial product was manufactured using an E. coli‑derived platform, rather than the highly purified formulation used in clinical trials, introduces concerns about batch consistency and potential contaminants that regulators must address.

Regulatory bodies in the European Union and beyond may feel pressure to re‑examine the data packages submitted for vaccine approval. The alleged discrepancy between trial and market batches could trigger formal investigations under the EU’s pharmacovigilance framework, potentially leading to additional post‑marketing studies or even temporary suspensions. Moreover, the reported figure of 1,200 suspected deaths—extrapolated to a possible 60,000 fatalities in Germany—could fuel public skepticism, influencing vaccine uptake rates and prompting lawmakers to demand greater transparency from manufacturers and health agencies.

Beyond the immediate controversy, the testimony underscores a broader demand for robust, independent safety monitoring of novel therapeutics. As the industry moves toward mRNA and other platform technologies, establishing clear standards for toxicology testing and batch verification becomes critical to maintaining confidence in rapid‑response medical interventions. Stakeholders—including investors, healthcare providers, and patients—will be watching how Pfizer and regulators respond, as the outcome may shape future pathways for emergency authorizations and set precedents for handling safety concerns in high‑stakes public health emergencies.